



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Graham Michael WYNNE et al.
Application No.: 10/752,342
Attorney Docket No.: OS-10001
Filed: January 06, 2004
Examiner: Susannah Lee
Title: (2-CARBOXAMIDO)(3-AMINOTHIOPHENE
COMPOUNDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: **Mail Stop Amendment**, Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

OSI Pharmaceuticals, Inc.

By

Shu M. Lee

Date

28 Oct. 2004

Mail Stop Amendment

Commissioner for Patents

U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants respectfully submit the documents itemized in the enclosed Form 1449 to the Examiner's attention. Copies of the documents, except for U.S. Patent documents – which the Patent Office has instructed Applicants not to submit, are also enclosed for the Examiner's review. Applicants respectfully request the Examiner initial the form and return a copy to the Applicant to indicate each document has been considered.

The significance of foreign language document WO 00/027819 is described in the specification at page 3, paragraph 11. Further, Applicants respectfully direct the Examiner's attention to U.S. Patent No. 6,448,277 that is in the same family as WO 00/027819, although somewhat different in scope.

This IDS is being submitted before issuance of any Office Action on the merits. Accordingly, no fee is needed. Nevertheless, the Examiner is authorized to charge any

deficiencies in fees and credit any overpayment to OSI Pharmaceuticals, Inc. Deposit Account No. **502783**.

Attorney for Applicants can be reached at the telephone number and address below.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Shu M. Lee". The signature is fluid and cursive, with the first name "Shu" and last name "Lee" being prominent.

Shu M. Lee
Attorney for Applicants
Registration No. 41,147
Telephone No. (631) 962-2056
or (516) 924-4035
Fax No. (631) 752-3880

October 27, 2004
OSI Pharmaceuticals, Inc.
58 South Service Road, Suite 110
Melville, NY 11747



LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/752,342
				Filing Date	January 06, 2004
				First Named Inventor	Graham Michael WYNNE
				Art Unit	1626
				Examiner Name	Susannah Lee
Sheet	1	of	1	Attorney Docket No.	OS-10001

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REFERENCE DESIGNATION	DOCUMENT NUMBER	PUBLICATION OR ISSUE DATE	INVENTOR	CLASS/ SUBCLASS
	A1	6,140,351	10-31-2000	Arnaiz et al.	514/336
	A2	5,968,965	10-19-1999	Dinsmore et al.	514/399
	A3	6,376,515	03-23-2002	Zhu et al.	514/318
	A4	6,410,561	06-25-2002	Shinkai et al.	514/313
	A5	6,207,693	03-27-2001	Setoi et al.	514/394
	A6	6,316,482	11-13-2001	Setoi et al.	514/394
	A7	6,448,277	09-10-2002	Altmann et al.	514/357

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	REFERENCE DESIGNATION	DOCUMENT NUMBER	PUBLICATION DATE	APPLICANT	COUNTRY
	B1	WO 00/027820	05-18-2000	Novartis and Schering	PCT
	B2	WO 99/032477	07-01-1999	Schering AG	PCT
	B3	WO 00/027819	05-18-2000	Schering and Novartis	PCT
	B4	WO 02/000651	01-03-2002	Dupont Pharm.	PCT
	B5	WO 01/019798	03-22-2001	Cor Therapeutics	PCT
	B6	WO 01/007050	02-01-2001	Schering Corp.	PCT
	B7	WO 01/064642	09-07-2001	Cor Therapeutics	PCT
	B8	WO 01/005763	01-25-2001	Acadia Pharm.	PCT
	B9	WO 02/066470	08-29-2002	Amgen Inc.	PCT
	B10	WO 02/068406	09-06-2002	Amgen Inc.	PCT
	B11	WO 02/055501	07-18-2002	Amgen Inc.	PCT
	B12	EP 0 832 061	04-01-1998	Fujisawa Pharm.	EP

EXAMINER INITIAL	REFERENCE DESIGNATION	OTHER ART (Include Author, Title, Date, Pages, etc.)

EXAMINER	Date Considered:
----------	------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.